Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Background
Enoblituzumab is an investigational monoclonal antibody that targets B7-H3 and has been enhanced using MacroGenics’ Fc Optimization platform. B7-H3 is a protein in the B7 family of immune regulator proteins. B7-H3 is widely expressed by a number of different tumor types and may play a key role in regulating the immune response to various types of cancer.
Clinical Development
Please refer to our most recent corporate deck on our Events & Presentations page for the latest clinical information available on enoblituzumab.
Our Rights
MacroGenics retains global rights to enoblituzumab.
Clinical Trials
- Enoblituzumab Phase 1 Study (NCT01391143)
- Enoblituzumab Combination Study with Pembrolizumab (NCT02475213)
- Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer (NCT04634825)
- (IST) Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer (NCT 02923180)
- (IST) FT516 and IL2 With Enoblituzumab for Ovarian Cancer (NCT04630769)
- (IST) Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer (HEAT) (NCT06014255)
Presentations & Publications
Relevant Publications and Presentations can be found at https://macrogenics.com/publications/.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.